EPISODE 106 | RELEASED February 2, 2021

What is FidoCure? | Ben Lewis Deep Dive

Ben Lewis of FidoCure dives deep on genetic testing and targeted therapy, on what FidoCure can and cannot do for your dog.


For many years, DNA sequencing has been a first line option for diagnosing and treating many human cancers, in a treatment that is often referred to as targeted therapy. Targeted therapy works by directly inhibiting the growth and replication of the cancer cells in certain types of tumors, and because of its targeted action it has shown high rates of tumor responsiveness in people. So, what happens when you take this science and apply it to dogs? Well, essentially the same thing, which is exciting and is exactly what we are talking about this week with Ben Lewis, the co-founder of FidoCure.

Lewis tells us about genomic sequencing as it relates to cancer-causing DNA mutations. He shares the science behind FidoCure, the types of dog tumors that they’ve had the most success with, as well as how all this biotechnology and science could really help improve the standard of care and the prognosis of many types of cancers in humans and their dogs.


Link to the Hemangiosarcoma paper by Guannan Wang and Nicola Mason: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708669/

Link to the Science Exchange website: https://www.scienceexchange.com/

Hosted By




Did You Find This Helpful? Share It with Your Pack!

Share on social media, download a PDF, print this out, or send this in an email to your veterinarian.

Editor's Picks